Higher risk of cardiovascular mortality linked with timolol

Article

Cardiovascular mortality tends to increase in black persons with diagnosed and treated open-angle glaucoma (OAG) and ocular hypertension (OH), and the risk of death and cardiovascular mortality are increased further in those patients treated with timolol, according to a paper published in the March 11, 2008 issue of the Archives of Ophthalmology.

Cardiovascular mortality tends to increase in black persons with diagnosed and treated open-angle glaucoma (OAG) and ocular hypertension (OH), and the risk of death and cardiovascular mortality are increased further in those patients treated with timolol, according to a paper published in the March 11, 2008 issue of the Archives of Ophthalmology.

Suh-Yuh Wu of Stony Brook University, NY (US) and colleagues conducted the Barbados Eye Study in 4092 participants, who were predominantly black and were aged 40-84 years at baseline. At baseline, 300 participants had glaucoma, of whom 141 had been diagnosed and treated.

After nine years, 764 (19%) participants were deceased. Mortality was unrelated to overall OAG at baseline after adjustment for confounders. However, cardiovascular mortality tended to increase in persons with previously diagnosed/treated OAG (relative risk [RR], 1.38, p=0.07) and was significantly higher with treatment involving timolol maleate (RR, 1.91, p=0.04). Cardiovascular deaths also tended to increase in persons with OH at baseline (n=498; RR, 1.28, p=0.06).

The results led the study authors to conclude that cardiovascular mortality within this population tended to increase in persons with previously diagnosed/treated OAG and OH. The excess mortality was particularly significant in patients treated with timolol (60%) either alone or in combination, and thus warrants further investigation.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.